GRM8 and neuroblastoma: By contrast, GRM8 is an appealing drug target, as it is predominantly expressed in neurons and its activation has been reported to protect undifferentiated neuroblastoma cells against doxorubicin (Jantas et al., 2016) and the mitochondrial toxin MPP4+ (Jantas et al., 2014).